April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Infliximab Therapy For Ocular Inflammatory Disorders-safety Profile
Author Affiliations & Notes
  • Mehrine Shaikh
    Ocular Immunology and Uveitis Fndn, Cambridge, Massachusetts
  • Footnotes
    Commercial Relationships  Mehrine Shaikh, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4257. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mehrine Shaikh; Infliximab Therapy For Ocular Inflammatory Disorders-safety Profile. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4257.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To examine the long term safety profile of Infliximab therapy for ocular inflammatory disease in the largest patient population published to date.

Methods: : This is a single-center, retrospective interventional case series. The charts of 107 patients with noninfectious uveitis treated with infliximab, either as monotherapy or in combination with another immunomodulatory therapy, were reviewed. Primary outcome measure was adverse effects while on infliximab therapy.

Results: : Infliximab was well tolerated in the 107 patients. The most common adverse effect was gastrointestinal discomfort in 6 patients (nausea, vomiting, abdominal pain or diarrhea), leucopenia in 4 patients, fatigue in 4 patients, rash in 4 patients. These resolved after reducing the dosage of the drug. Two patients had a definitive diagnosis of lupus which required cessation of therapy. One patient had symptoms suggestive of lupus like reaction with joint pain and an ANA titer of 1:160 but negative ssDNA and dsDNA. Regardless, infliximab was stopped in this patient. Thirteen had to stop infliximab due to development of adverse effects.

Conclusions: : Infliximab was well tolerated has a favorable risk-benefit ratio for the care of patients with vision threatening ocular inflammatory disease.

Keywords: autoimmune disease • clinical (human) or epidemiologic studies: outcomes/complications • immunomodulation/immunoregulation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.